PTC Therapeutics Expands International Commercial Team

            PTC Therapeutics Expands International Commercial Team

  PR Newswire

  SOUTH PLAINFIELD, New Jersey, Feb. 25, 2014

SOUTH PLAINFIELD, New Jersey, Feb. 25, 2014 /PRNewswire/ -- PTC Therapeutics,
Inc. (NASDAQ: PTCT) today announced the appointment of Guido Schopen, M.D. to
General Manager and Head of Medical Affairs for Europe. Dr. Schopen will be
responsible for European commercial operations, reporting to Mark Rothera,
Chief Commercial Officer of PTC.

(Logo: )

"We are delighted to welcome Dr. Schopen to our team where he will play a key
leadership role in building out our European commercial capabilities," stated
Mr. Rothera. "PTC is expanding its commercial footprint with a near term focus
on certain pre-approval activities. Our ultimate goal is to build a specialty
global commercial organization to bring ataluren to Duchenne muscular
dystrophy and cystic fibrosis patients as soon as possible following
regulatory approvals. Dr. Schopen's medical and commercial expertise will be
instrumental in achieving this goal."

Prior to joining PTC, Dr. Schopen was Vice President, Global Commercial
Operations and Medical Affairs for TiGenix NV, where he oversaw both the
commercialization of the first approved cell therapy product for cartilage
repair in Europe (ChondroCelect®) and the clinical development strategy of the
company's adult stem cell programs. Dr. Schopen has more than 20 years of
experience in the industry with leadership positions in sales, marketing,
business development, life-cycle management, clinical development and general
management at ICI Pharma, UCB Pharma, Bayer HealthCare and Behringwerke. He
received his undergraduate and medical degrees from the University of RWTH
Aachen, Germany.

"I am pleased to join PTC at this exciting time in the company's evolution.
Ataluren is a novel product candidate with significant potential across
multiple genetic disorders," stated Dr. Schopen. "PTC's unrelenting commitment
to bring this potentially disease modifying therapy to patients suffering from
rare disorders is impressive and I look forward to being part of that effort."

About PTC Therapeutics, Inc.

PTC is biopharmaceutical company focused on the discovery and development of
orally administered, proprietary small molecule drugs that target
post-transcriptional control processes. Post-transcriptional control processes
regulate the rate and timing of protein production and are essential to proper
cellular function. PTC's internally discovered pipeline addresses multiple
therapeutic areas, including rare disorders, oncology and infectious diseases.
PTC has developed proprietary technologies that it applies in its drug
discovery activities and which form the basis for collaborations with leading
biopharmaceutical companies. For more information on the company, please visit
our website .


Any statements in this press release about future expectations, plans and
prospects for PTC, the development of and potential market for PTC's product
candidates, our plans to develop a global commercial organization, our
clinical trials, our current and planned regulatory submissions, our earlier
stage programs, and other statements containing the words "anticipate,"
"believe," "estimate," "expect," "intend," "may," "plan" "predict," "project,"
"target," "potential," "will," "would," "could," "should," "continue," and
similar expressions, constitute forward-looking statements within the meaning
of The Private Securities Litigation Reform Act of 1995. Forward-looking
statements involve substantial risks and uncertainties that could cause our
future results, performance or achievements to differ significantly from those
expressed or implied by these forward-looking statements. Such risks and
uncertainties include, among others, those related to the initiation and
conduct of clinical trials, availability of data from clinical trials,
expectations for regulatory approvals, our scientific approach and general
development progress, the availability or commercial potential of our product
candidates and other factors discussed in the "Risk Factors" in the most
recent Quarterly Report, which is on file with the Securities and Exchange
Commission. In addition, the forward-looking statements included in this press
release represent PTC's views only as of the date of this press release. We
anticipate that subsequent events and developments will cause our views to
change. However, while we may elect to update these forward-looking statements
at some point in the future, the Company specifically disclaims any obligation
to do so. These forward-looking statements should not be relied upon as
representing PTC's views as of any date subsequent to the date of this press

Contact: Jane Baj, PTC Therapeutics, Inc., +1 (908) 912-9167,
Press spacebar to pause and continue. Press esc to stop.